Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer
This research study is studying an immune-based cancer drug as a possible treatment for prostate cancer.
The drug involved in this study is:
A Phase 2 Study of Nivolumab in Patients with High-Risk Biochemically Recurrent Prostate Cancer
- ClinicalTrials.gov Identifier: NCT03637543
- Protocol Number: 18-249
- Principal Investigator: David Einstein
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required